Bloomberg Intelligence BI Weekend: Live Nation Suit, Micron Earnings, Kimmel Return
Sep 26, 2025
The podcast dives into the FTC lawsuit against Live Nation, revealing how Ticketmaster allegedly profited from ticket bots. Micron's surprisingly low stock performance despite decent earnings raises eyebrows as AI and supply issues loom large. Pfizer's $4.9 billion acquisition of MetSera highlights their strategic pivot into obesity drugs. Furthermore, Jimmy Kimmel's return to late night brings up the financial struggles of the industry, while T-Mobile prepares for leadership changes amidst competitive dynamics. Starbucks faces restructuring with store closures.
AI Snips
Chapters
Transcript
Episode notes
Live Nation Faces Dual Legal Pressure
- The FTC and DOJ allege Live Nation knowingly let bots and large-scale resellers exploit Ticketmaster while profiting from resale fees.
- The DOJ seeks structural remedies while the FTC suit likely settles due to massive per-violation fines.
AI Demand Tightens Memory Supply
- Micron's results disappointed because investors expected outsized AI-driven demand and pricing strength.
- High-bandwidth memory for AI is constraining overall DRAM supply and supporting an extended upcycle.
How MetSera’s Drugs Work
- Sam Fazelli describes MetSera's amylin and GLP-1 candidate profiles and their effect on appetite and insulin signaling.
- He notes the key trade-off is efficacy versus tolerability and dosing frequency for patient adherence.